The drugmaker said successful results prompted an independent Data Monitoring Committee to recommend stopping the trial. The news follows an uneven week of pipeline drug news.
Analyses by Jefferies indicate that although doctors are interested in the experimental anti-cholesterol drugs, CV data will be a critical differentiator.
The state's attorney general says the drugmakers did not reveal that the drug could have a different impact—if any—on patients with East Asian or Pacific Islander heritage.
Researchers find that Canada has been a significant contributor to Zetia sales.
Researchers say saturated fat may not cause heart disease, but critics say the study is too narrow.
The FDA approved the blood drug to prevent deep vein thrombosis and pulmonary embolism among hip- and knee-replacement patients. The approval means BMS and Pfizer may encroach upon the territory of J&J's Xarelto.
The Thousand Oaks, Calif. company says its cholesterol-lowering antibody hit its clinical trial endpoint among rare disease patients.
The company said it used "inappropriate expressions" in promotions of a blood pressure medication.
Roche said an onartuzumab and Tarceva mix did not help advanced non-small cell lung cancer patients with MET-positive tumors.
The FDA rejected J&J's expanded indication request a third time.
The Cleveland Clinic finds that 75% of Americans don't worry about dying of heart disease, even though it's the country's leading killer.
A sealed complaint, reported on by the Wall Street Journal, builds on concerns that were already surrounding the now-controversial Plato study.
Positive results from a Phase-III trial edge Amgen's evolocumab closer to approval, though it's still behind rivals in the PCSK9 race.
The FDA panel voted 10-1 for the drug. The assessment included patient weight and health recommendations.
An FDA committee is poised to review a new Primatene Mist in February.
The warfarin replacement will be evaluated in a post-trial safety study, regulators said last Friday.
The American College of Cardiology is contributing its Pinnacle registry to identify clinical trial patients.
The fine is for Pradaxa documents that have gone missing. The company is accused of hiding risk information about its blood thinner.
A poll indicates new cholesterol guidelines won't shake up the statin market in 2014.
The drugmaker revealed the data a year after stopping a Phase III trial.
Phase III clinical trial results underwhelm investors who feel on-market drugs offer better patient value.
The company is rolling out two new clinical trials, and Phase I data suggests an antidote could be on its way.
The calculator meant to help doctors use the new cholesterol guidelines appears to be flawed.
Aggressive new recommendations for treating patients at high risk of cardiovascular disease could significantly alter the treatment landscape.
The drugmaker's latest financial plans could power it through mid-2015.
An investigational cardiovascular heart drug failed to reduce the risk of heart attack or stroke, a miss which some on Wall Street say raises questions about the drugmaker's ability to deliver in late-stage trials.
The FDA told the drugmaker in a letter before the December PDUFA date that evidence does not support an expanded indication.
An advisory committee voted 9 to 2 against expanding the drug's indication.
Three former workers are accused of giving proprietary data to a drug company abroad.
The drug maker says it is accelerating development of new drugs and focusing on expanding indications of current ones.